Nitin Kabra, MD
Advanced Heart Failure and Transplant Cardiology · Plano, TXNPI 1558604710
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $58,463 of the $67,751 with a category attached, or 86.3%. E.r. Squibb & Sons, L.L.C. accounts for 91.6% of it on its own, with 27 other manufacturers making up the rest. 2025 is the largest year on record at $30,373, more than ten times the $309 reported in 2021.
Across 243 payments — averaging $278.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$62K
- Abbott$2K
- Merck$504
- Abiomed$354
- AstraZeneca$354
- Alnylam Pharmaceuticals Inc.$280
- plus $2K from 22 others
Across 1 payment — averaging $65.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abiomed$66
What the payments were for
- Consulting fees$9001%
- Speaking & faculty fees$58,46386%
- Travel & lodging$1,6452%
- Food & beverage$6,70310%
- Education$400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 65 | $62,054 |
| Abbott | 36 | $2,194 |
| Merck | 25 | $504 |
| Abiomed | 5 | $354 |
| AstraZeneca | 18 | $354 |
| Alnylam Pharmaceuticals Inc. | 10 | $280 |
| Novo Nordisk | 13 | $263 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $246 |
| Pfizer | 9 | $173 |
| Cvrx, Inc. | 8 | $168 |
| Bridgebio Pharma, Inc. | 3 | $167 |
| Impulse Dynamics (USA) Inc. | 2 | $162 |
| Boehringer Ingelheim | 5 | $131 |
| Novartis | 5 | $129 |
| Lexicon Pharmaceuticals, Inc. | 5 | $104 |
| Scpharmaceuticals Inc. | 4 | $84 |
| Boston Scientific | 3 | $68 |
| Daiichi Sankyo Inc. | 2 | $53 |
| Esperion Therapeutics, Inc. | 2 | $39 |
| Kestra Medical Technology Services, Inc. | 2 | $39 |
| Bayer | 2 | $36 |
| Sanofi | 1 | $32 |
| Amgen | 1 | $29 |
| Procyrion, Inc. | 1 | $21 |
| United Therapeutics Corporation | 1 | $18 |
| Vifor Pharma, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$60,773
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$1,005
- OPTIMIZER$288
- CARDIOMEMS$222
- Impella$164
- HeartMate 3 Left Ventricular Assist Device$148
- Attruby$105
How this compares
$67,751 in reported general payments places this provider in the 75th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
See all advanced heart failure and transplant cardiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 67 | $1,539,226 |
| CamzyosMavacamten | 89 | $721,144 |
| EntrestoSacubitril/Valsartan | 139 | $209,927 |
| FarxigaDapagliflozin Propanediol | 109 | $137,642 |
| JardianceEmpagliflozin | 91 | $107,868 |
| EliquisApixaban | 28 | $40,444 |
| OzempicSemaglutide | 36 | $33,624 |
| WegovySemaglutide | 15 | $20,627 |
| Metoprolol Succinate | 218 | $3,783 |
| Torsemide | 139 | $3,346 |
| Potassium Chloride | 61 | $2,859 |
| Spironolactone | 297 | $2,221 |
| Eplerenone | 29 | $2,177 |
| Bumetanide | 44 | $1,954 |
| Losartan Potassium | 180 | $1,877 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $173 | $1,579,67095 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $62,054 | $721,14489 claims |
| NovartisEntresto | $129 | $209,927139 claims |
| AstraZenecaFarxiga | $354 | $137,642109 claims |
| Boehringer IngelheimJardiance | $131 | $107,86891 claims |
| Novo NordiskOzempic, Wegovy | $263 | $54,25251 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
Other advanced heart failure and transplant cardiology in Plano
- Aasim AfzalPlano$336K
- Akash RusiaPlano$13K
- Gregory MilliganPlano$7K
- Robert GottliebDallas$717K
- Albert HicksTemple$613K
- Allen AndersonSan Antonio$413K
- Martin BerkDallas$379K
- Kunjan BhattAustin$324K
- Barry TrachtenbergHouston$306K
- Shelley HallDallas$254K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.